Harrow, Inc. Increase (Decrease) in Interest Payable, Net
Harrow, Inc. (HROW) reported Increase (Decrease) in Interest Payable, Net of $1.69 million for the 158-month period ending 2011-09-30, per its 10-Q filed 2012-02-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2012-02-23
- Harrow, Inc. increase (decrease) in interest payable, net for the quarter ending 2011-09-30 was $18.90K, a 0.00% change year-over-year.
- Harrow, Inc. increase (decrease) in interest payable, net for the quarter ending 2010-09-30 was $18.90K.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 155 month | Increase (Decrease) in Interest Payable, Net 158 month |
|---|---|---|---|---|---|
| 2011-09-30 | $18.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23 | $56.09K 10-Q · filed 2012-02-23 | $1.69M 10-Q · filed 2012-02-23 | ||
| 2011-06-30 | $37.19K 10-Q · filed 2012-02-23 | $1.67M 10-Q · filed 2012-02-23 | |||
| 2010-09-30 | $18.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23 | $36.58K 10-Q · filed 2012-02-23 | |||
| 2010-06-30 | $17.67K 10-Q · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |